Neuropathologic basis of quantitative susceptibility mapping in the substantia nigra: contributions of tau, pigmented neurons, and iron - Scorecard - MDSpire
Advertisement
Neuropathologic basis of quantitative susceptibility mapping in the substantia nigra: contributions of tau, pigmented neurons, and iron
Clinical Scorecard: Pathological Insights into Quantitative Susceptibility Mapping in the Substantia Nigra: The Roles of Tau, Pigmented Neurons, and Iron Accumulation
At a Glance
Category
Detail
Condition
Neurodegenerative disorders with nigral involvement including Lewy body disease (LBD), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Alzheimer’s disease (AD)
Key Mechanisms
Iron accumulation, tau pathology, pigmented neuron density, and neuroinflammation contributing to magnetic susceptibility changes in the substantia nigra
Target Population
Patients with neurodegenerative diseases exhibiting parkinsonism or cognitive impairment undergoing MRI and neuropathologic evaluation
Care Setting
Specialized neurology and neuropathology centers with access to advanced MRI techniques and postmortem brain analysis
Key Highlights
Quantitative susceptibility mapping (QSM) detects increased magnetic susceptibility in the substantia nigra due to iron accumulation, tau burden, and neuron density changes.
Elevated QSM values are observed in LBD (including PD and DLB), tauopathies (PSP, CBD), and some AD cases with nigral neuron loss, complicating interpretation.
Digital pathology combined with machine learning enables quantification of iron deposition, tau burden, and pigmented neuron density in substantia nigra subregions correlating with QSM.
Guideline-Based Recommendations
Diagnosis
Use QSM MRI to assess magnetic susceptibility changes in the substantia nigra as a potential biomarker for neurodegenerative diseases with nigral involvement.
Perform comprehensive clinical evaluation including parkinsonism features and cognitive assessments (MMSE, CDR-SB, UPDRS-III) to characterize patient phenotype.
Confirm neuropathologic diagnosis postmortem using immunohistochemistry for α-synuclein, phosphorylated tau, and iron staining to delineate disease-specific pathology.
Management
Interpret elevated QSM values in the context of clinical and neuropathologic findings due to overlapping iron and tau contributions across diseases.
Consider the presence of tau pathology and pigmented neuron loss alongside iron accumulation when evaluating disease progression and therapeutic targets.
Monitoring & Follow-up
Monitor parkinsonism severity using standardized scales such as UPDRS-III or modified versions to track motor symptom progression.
Use longitudinal MRI with QSM sequences to assess changes in substantia nigra susceptibility as a surrogate marker of disease progression.
Risks
Be aware that microbleeds and other MRI artifacts can affect iron measurements and QSM accuracy, necessitating careful image quality control.
Recognize that amyloid-β burden and α-synuclein pathology may not correlate consistently with QSM, limiting their utility in susceptibility interpretation.
Patient & Prescribing Data
Individuals with clinically and neuropathologically confirmed neurodegenerative diseases involving the substantia nigra
QSM provides insight into underlying pathology but does not directly guide pharmacologic treatment; clinical management should integrate multimodal assessments.
Clinical Best Practices
Combine QSM MRI with detailed clinical and neuropathologic evaluation for accurate diagnosis and understanding of nigral pathology.
Utilize machine learning-based digital pathology to quantify iron, tau, and neuron density for research and potential biomarker development.
Segment substantia nigra into four quadrants (ventromedial, ventrolateral, dorsomedial, dorsolateral) for precise regional analysis correlating with QSM findings.
by Daisuke Ono, Sravya Kondrakunta, Elijah Mak, Scott A. Przybelski, Angela J. Fought, Christopher G. Schwarz, Melissa E. Murray, Aivi Nguyen, Ross R. Reichard, Matthew L. Senjem, Jeffrey L. Gunter, Clifford R. Jack, Toji Miyagawa, Leah K. Forsberg, Julie A. Fields, Rodolfo Savica, Vijay K. Ramanan, David T. Jones, Hugo Botha, Erik K. St. Louis, David S. Knopman, Neill R. Graff-Radford, Gregory S. Day, Tanis J. Ferman, Walter K. Kremers, Val J. Lowe, Ronald C. Petersen, Bradley F. Boeve, Dennis W. Dickson, Kejal Kantarci
